<?xml version="1.0"?>
<npl:medprod xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mpa="urn:schemas-npl:mpa:12" xsi:schemaLocation="urn:schemas-npl:instance:12 ../schemas/npl-schema_12.0.xsd" xmlns:npl="urn:schemas-npl:instance:12">
  <mpa:nplid>20220511000038</mpa:nplid>
  <npl:names>
    <mpa:medprodname v="Fascinex 240" />
    <mpa:medprodnamelegal v="Fascinex 240" />
  </npl:names>
  <mpa:strength-text>
    <mpa:v>240 mg/ml</mpa:v>
  </mpa:strength-text>
  <mpa:pharmaceutical-form-lx v="ORASUS" lexicon="pharmaceutical-form-lx" />
  <npl:organizations>
    <mpa:organization>
      <mpa:organization-lx v="ID18MBMX8IEFQTISRV" />
      <mpa:organization-role-lx v="MAH" lexicon="organization-role-lx" />
    </mpa:organization>
  </npl:organizations>
  <npl:special-permission-info>
    <mpa:special-permission-nca-approval-country v="FRA" lexicon="country-lx" />
    <mpa:special-permission-idnumber v="FR/V/2861908 8/2009" />
  </npl:special-permission-info>
  <mpa:productclass-lx v="LIC" lexicon="productclass-lx" />
  <mpa:prescription-lx v="1" lexicon="prescription-lx" />
  <npl:classifications>
    <mpa:atc-code-lx v="QP52AC01" />
    <mpa:controlled-medicinal-product-lx v="N" lexicon="yesno-lx" />
    <mpa:narcotic-class-lx v="0" lexicon="narcotic-classification-lx" />
  </npl:classifications>
  <npl:flags>
    <mpa:salesstopped v="N" lexicon="yesno-lx" />
    <mpa:biological-medprod-pharmaceutical-legislation v="N" lexicon="yesno-lx" />
    <mpa:antimicrobial v="N" lexicon="yesno-lx" />
    <mpa:reserved-hum v="N" lexicon="yesno-lx" />
  </npl:flags>
  <npl:pharmaceutical-products>
    <npl:pharmaceutical-product id="ID1VT2YY1KRV0CHSRV">
      <npl:composition>
        <npl:ingredient id="ID1000000000302214" presentation-substance-name="Y">
          <mpa:ingredient-role-lx v="ACTI" lexicon="ingredient-role-lx" />
          <mpa:quantity-unit-alt-lx v="QS" lexicon="quantity-unit-alt-lx" />
          <mpa:substance-lx v="ID1QSZMFI1U6F3LCSR" />
        </npl:ingredient>
      </npl:composition>
      <mpa:comp-ref-quantity-lx v="FGE" lexicon="comp-ref-quantity-lx" />
    </npl:pharmaceutical-product>
  </npl:pharmaceutical-products>
  <npl:withdrawal-periods>
    <npl:withdrawal-period>
      <mpa:withdrawal-tissue-lx v="1" lexicon="withdrawal-tissue-lx" />
      <mpa:withdrawal-period v="56" />
      <mpa:withdrawal-period-unit-lx v="DAYS" lexicon="withdrawal-period-unit-lx" />
      <npl:species-of-animals>
        <mpa:species-of-animal-lx v="001" lexicon="species-of-animal-lx" />
      </npl:species-of-animals>
    </npl:withdrawal-period>
    <npl:withdrawal-period comment="Ej till kor som producerar mjölk för humankonsumtion.&#xA;Kvigor och sinkor: 6,5 dagar efter kalvning om intervallet mellan behandling och kalvning är 6 veckor eller mer. 7 veckor om intervallet mellan behandling och kalvning är mindre än 6 veckor.&#xA;Gäller vid dosen 12 mg triklabendazole/kg kroppsvikt (= 5 ml/100 kg kroppsvikt) som oral engångsdos.">
      <mpa:withdrawal-tissue-lx v="2" lexicon="withdrawal-tissue-lx" />
      <mpa:withdrawal-period v="9999" />
      <mpa:withdrawal-period-unit-lx v="MONTHS" lexicon="withdrawal-period-unit-lx" />
      <npl:species-of-animals>
        <mpa:species-of-animal-lx v="001" lexicon="species-of-animal-lx" />
      </npl:species-of-animals>
    </npl:withdrawal-period>
  </npl:withdrawal-periods>
  <npl:packages>
    <npl:package>
      <mpa:nplpackid>20220511100387</mpa:nplpackid>
      <mpa:pack-text>
        <mpa:v>Licensförpackning</mpa:v>
      </mpa:pack-text>
      <npl:prescription>
        <mpa:otc v="N" lexicon="yesno-lx" />
      </npl:prescription>
    </npl:package>
  </npl:packages>
</npl:medprod>
